|
1
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar
|
|
2
|
Delbaldo C, Michiels S, Rolland E, et al:
Second or third additional chemotherapy drug for non-small cell
lung cancer in patients with advanced disease. Cochrane Database
Syst Rev. 17:CD0045692007.
|
|
3
|
Hanahan D: The hallmarks of cancer. Cell.
100:57–70. 2000. View Article : Google Scholar
|
|
4
|
Vignot S, Faivre S, Aguirre D and Raymond
E: mTOR-targeted therapy of cancer with rapamycin derivatives. Ann
Oncol. 16:525–537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaw RJ and Cantley LC: Ras, PI (3) K and
mTOR signalling controls tumour cell growth. Nature. 441:424–430.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
LoPiccolo J, Blumenthal GM, Bernstein WB
and Dennis PA: Targeting the PI3K/Akt/mTOR pathway: effective
combinations and clinical considerations. Drug Resist Updat.
11:32–50. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sabers CJ, Martin MM, Brunn GJ, et al:
Isolation of a protein target of the FKBP12-rapamycin complex in
mammalian cells. J Biol Chem. 270:815–822. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lorenz MC and Heitman J: TOR mutations
confer rapamycin resistance by preventing interaction with
FKBP12-rapamycin. J Biol Chem. 270:27531–27537. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Balsara BR, Pei J, Mitsuuchi Y, et al:
Frequent activation of AKT in non-small cell lung carcinomas and
preneoplastic bronchial lesions. Carcinogenesis. 25:2053–2059.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wislez M, Spencer ML, Izzo JG, et al:
Inhibition of mammalian target of rapamycin reverses alveolar
epithelial neoplasia induced by oncogenic K-ras. Cancer Res.
65:3226–3235. 2005.PubMed/NCBI
|
|
11
|
Marinov M, Fischer B and Arcaro A:
Targeting mTOR signaling in lung cancer. Crit Rev Oncol Hematol.
63:172–182. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gridelli C, Maione P and Rossi A: The
potential role of mTOR inhibitors in non-small cell lung cancer.
Oncologist. 13:139–147. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Muthukkumar S, RaMesh TM and Bondada S:
Rapamycin, a potent immunosuppressive drug, causes programmed cell
death in B lymphoma cells. Transplantation. 60:264–270. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tirado OM, Mateo-Lozano S and Notario V:
Rapamycin induces apoptosis of JN-DSRCT-1 cells by increasing the
Bax: Bcl-xL ratio through concurrent mechanisms dependent and
independent of its mTOR inhibitory activity. Oncogene.
24:3348–3357. 2005. View Article : Google Scholar
|
|
15
|
Zhang JF, Liu JJ, Lu MQ, et al: Rapamycin
inhibits cell growth by induction of apoptosis on hepatocellular
carcinoma cells in vitro. Transpl Immunol. 17:162–168. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vega F, Medeiros LJ, Leventaki V, et al:
Activation of mammalian target of rapamycin signaling pathway
contributes to tumor cell survival in anaplastic lymphoma
kinase-positive anaplastic large cell lymphoma. Cancer Res.
66:6589–6597. 2006. View Article : Google Scholar
|
|
17
|
Aguirre D, Boya P, Bellet D, et al: Bcl-2
and CCND1/CDK4 expression levels predict the cellular effects of
mTOR inhibitors in human ovarian carcinoma. Apoptosis. 9:797–805.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Huang S, Liu LN, Hosoi H, Dilling MB,
Shikata T and Houghton PJ: p53/p21CIP1 cooperate in
enforcing rapamycin-induced G1 arrest and determine the cellular
response to rapamycin. Cancer Res. 61:3373–3381. 2001.
|
|
19
|
Huang S, Shu L, Easton J, et al:
Inhibition of mammalian target of rapamycin activates apoptosis
signal-regulating kinase 1 signaling by suppressing protein
phosphatase 5 activity. J Biol Chem. 279:36490–36496. 2004.
View Article : Google Scholar
|
|
20
|
Calastretti A, Rancati F, Ceriani MC,
Asnaghi L, Canti G and Nicolin A: Rapamycin increases the cellular
concentration of the BCL-2 protein and exerts an anti-apoptotic
effect. Eur J Cancer. 37:2121–2128. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Boffa DJ, Luan F, Thomas D, et al:
Rapamycin inhibits the growth and metastatic progression of
non-small cell lung cancer. Clin Cancer Res. 10:293–300. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Buck E, Eyzaguirre A, Brown E, et al:
Rapamycin synergizes with the epidermal growth factor receptor
inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and
breast tumors. Mol Cancer Ther. 5:2676–2684. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kishimoto M, Kohno T, Okudela K, et al:
Mutations and deletions of the CBP gene in human lung cancer. Clin
Cancer Res. 11:512–519. 2005.PubMed/NCBI
|
|
24
|
Okabe T, Okamoto I, Tamura K, et al:
Differential constitutive activation of the epidermal growthfactor
receptor in non-small cell lung cancer cells bearing EGFR gene
mutation and amplification. Cancer Res. 67:2046–2053. 2007.
View Article : Google Scholar
|
|
25
|
Mori T, Okamoto H, Takahashi N, Ueda R and
Okamoto T: Aberrant overexpression of 53BP2 mRNA in lung cancer
cell lines. FEBS Lett. 465:124–128. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park MJ, Shimizu K, Nakano T, et al:
Pathogenetic and biologic significance of TP14ARF alterations in
nonsmall cell lung carcinoma. Cancer Genet Cytogenet. 141:5–13.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagai Y and Miyazawa H: Genetic
heterogeneity of the epidermal growth factor receptor in non-small
cell lung cancer cell lines revealed by a rapid and sensitive
detection system, the peptide nucleic acid-locked nucleic acid PCR
clamp. Cancer Res. 65:7276–7282. 2005. View Article : Google Scholar
|
|
28
|
Kluck RM, Bossy-Wetzel E, Green DR and
Newmeyer DD: The release of cytochrome c from mitochondria: a
primary site for Bcl-2 regulation of apoptosis. Science.
275:1132–1136. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
del Peso L, Gonzalez-Garcia M, Page C,
Herrera R and Nunez G: Interleukin-3-induced phosphorylation of BAD
through the protein kinase Akt. Science. 278:687–689.
1997.PubMed/NCBI
|
|
30
|
Gardai SJ, Hildeman DA, Frankel SK, et al:
Phosphorylation of Bax Ser184 by Akt regulates its activity and
apoptosis in neutrophils. J Biol Chem. 279:21085–21095. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wangpaichitr M, Wu C, You M, et al:
Inhibition of mTOR restores cisplatin sensitivity through
down-regulation of growth and anti-apoptotic proteins. Eur J
Pharmacol. 591:124–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Migita K, Eguchi K, Ichinose Y, et al:
Effects of rapamycin on apoptosis of rheumatoid synovial cells.
Clin Exp Immunol. 108:199–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gross A, McDonnell JM and Korsmeyer SJ:
BCL-2 family members and the mitochondria in apoptosis. Genes Dev.
13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang YJ, Duan Y and Zheng XF: Targeting
the mTOR kinase domain: the second generation of mTOR inhibitors.
Drug Discov Today. 16:325–331. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Serra V, Markman B, Scaltriti M, et al:
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and
inhibits the growth of cancer cells with activating PI3K mutations.
Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
|
